Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy

AKINCI B., DEMİR T., Saygili S., Yener S., ALACACIOĞLU İ., Saygili F., ...More

DIABETES RESEARCH AND CLINICAL PRACTICE, vol.81, no.1, pp.93-96, 2008 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 81 Issue: 1
  • Publication Date: 2008
  • Doi Number: 10.1016/j.diabres.2008.03.003
  • Journal Name: DIABETES RESEARCH AND CLINICAL PRACTICE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.93-96
  • Keywords: diabetes, pregnancy, fibrinolysis, TAFI, PAI-1, TAFI ANTIGEN, INSULIN-RESISTANCE, MELLITUS, ASSOCIATION, DYSFUNCTION, PAI-1, STATE
  • Dokuz Eylül University Affiliated: Yes

Abstract

Pregnancy is a prothrombotic condition with increased levels of several circulating coagulation factors. Decreased fibrinolytic activity has been shown in gestational diabetes. Gestational diabetes has been found to be associated with higher plasma plasminogen activator inhibitor-1 (PAI-1) antigen levels than normal pregnancy. The aim of the present study is to investigate the effect of gestational diabetes on plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels.